BRAF and familial pancreatic carcinoma: Recently, we reported that TRAB is efficacious on an osteosarcoma cisplatinum-resistant lung metastasis [67], a BRAF-V600E mutated melanoma [30, 32] and a gemcitabine (GEM)-resistant pancreatic cancer [25].